drugset / Trial / NCT05553093

Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

NCT05553093

Phase 4 Recruiting 150 enrolled Nanjing First Hospital, Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Effects of Tirzepatide on the occurrence and development of cognitive impairment in diabetic patients and its associated pattern of changes in brain neural network characteristics.

Timeline

Start
2022-03-15
Primary completion
2023-12-31
Completion
2027-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 5 mg Other
Subject Tirzepatide Peptide 10 mg Other
Subject Tirzepatide Peptide 15 mg Other
Comparator insulin glargine Protein / enzyme biologic 6 iu Other